LH
Labcorp Holdings Inc.
LH has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over LH overall, supported by stronger modeled upside and stronger fundamentals.
LH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Stable | |
| Stable |
LH's profitability is currently healthy, and its revenue, cash flow and balance sheet are stable.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
LH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 11x | $136 | -63% |
| Forward | 19x | $372 | — |
| Fair | 24x | $296 | -20% |
| Current | 31x | $372 | — |
| Expensive | 41x | $500 | +34% |
Historical ranges are pointers, not guarantees.
LH's PE is in its expensive range at 31x. If earnings grow as analysts expect, today's price would be 19x next year's earnings, in its fair range.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over LH in the historical PE scenario, which offers more potential upside but is not a forecast.
LH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Stable | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for LH, with profitability holding steady.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over LH on the outlook, with more favorable profitability expectations.
LH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $19.25 | +58% |
| Q3 2026 | $12.19 | +20% |
| Q2 2026 | $12.09 | +33% |
| Q1 2026 | $11.29 | +30% |
| Q4 2025 | $10.46 | +18% |
| Q3 2025 | $10.20 | +94% |
| Q2 2025 | $9.08 | +69% |
| Q1 2025 | $8.67 | +71% |
| Q4 2024 | $8.84 | +85% |
LH has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
LH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $3.8B | +6.9% |
| Q2 2026 | $3.7B | +5.8% |
| Q1 2026 | $3.5B | +5.8% |
| Q4 2025 | $3.5B | +5.6% |
| Q3 2025 | $3.6B | +8.6% |
| Q2 2025 | $3.5B | +9.5% |
| Q1 2025 | $3.3B | +5.3% |
| Q4 2024 | $3.3B | +9.8% |
LH's revenue has grown year over year for 10 quarters in a row: $3.8B last quarter, up 6.9% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 11% | -0.6 points |
| Q2 2026 | 12% | +0.9 points |
| Q1 2026 | 11% | +1 points |
| Q4 2025 | 7.6% | +1.1 points |
| Q3 2025 | 11% | +3.4 points |
| Q2 2025 | 11% | +2 points |
| Q1 2025 | 9.8% | -0.4 points |
| Q4 2024 | 6.5% | +11 points |
LH has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over LH on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
LH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $412.2M | +47% |
| Q2 2026 | $313.9M | -42% |
| Q1 2026 | $70.5M | +$178M |
| Q4 2025 | $490.3M | -26% |
| Q3 2025 | $280.5M | +74% |
| Q2 2025 | $542.7M | +25% |
| Q1 2025 | -$107.5M | +$56.1M |
| Q4 2024 | $665.1M | +61% |
LH still generates free cash flow, though less than at its 2021 peak: $1.3B over the past year.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR usually generates cash, though not every quarter: the latest was −$1.2B, but it generated $4.1B over the past year.
LH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.5% | -400K shares |
| 1 year | -2.5% | -2.1M shares |
| 3 years | -6.2% | -5.4M shares |
| 5 years | -16% | -15.5M shares |
| Available history | -17% | -17M shares |
LH has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | $353.8M |
| Q1 2026 | $98M |
| Q4 2025 | $225M |
| Q3 2025 | $25M |
| Q4 2024 | $75.1M |
| Q3 2024 | $75M |
| Q4 2023 | $9M |
LH spent $677M buying back its own shares over the past year.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
LH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.5x | Moderate |
| Q2 2026 | 2.6x | Moderate |
| Q1 2026 | 2.5x | Moderate |
| Q4 2025 | 2.5x | Moderate |
| Q3 2025 | 2.2x | Moderate |
| Q2 2025 | 2.4x | Moderate |
| Q1 2025 | 3.0x | Moderate |
| Q4 2024 | 2.8x | Moderate |
LH's net debt is about 2.5 years of its operating earnings (EBITDA), up from 2.2 years a year ago.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over LH on leverage, with a lower net debt burden relative to earnings.
LH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 74.6 | Overbought |
| Stochastic | 91.4 | Overbought |
LH's weekly RSI is 75 (overbought) and its Stochastic is 91 (overbought).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
LH PE vs Healthcare Sector
| Metric | LH | Sector median | Relative |
|---|---|---|---|
| PE | 31x | 26x | 18% above |
| PE % | 77 | 29 | 48 pts above |
LH is trading at 31x earnings, a 18% premium to the Healthcare sector's median of 26x.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over LH on valuation relative to its sector.
LH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $334.7 | 11% above |
| 20 week MA | $319.9 | 16% above |
| 50 week MA | $286.8 | 30% above |
| 100 week MA | $270.3 | 38% above |
| 200 week MA | $240.9 | 55% above |
LH is in an uptrend: it's above all five of its weekly moving averages, and 55% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
LH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $145.5 | $175.1 | +20% |
| 2021 | $175.1 | $259.4 | +48% |
| 2022 | $259.4 | $199.0 | -23% |
| 2023 | $199.0 | $227.3 | +14% |
| 2024 | $227.3 | $230.4 | +1.4% |
| 2025 | $230.4 | $253.9 | +10% |
| 2026 YTD | $253.9 | $372.3 | +47% |
LH has finished higher in five of the last six years. It's up 47% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over LH on returns for 2026, with the stronger performance.